translocation of CD8 T lymphocytes to the gut and the development of LGI a-GVHD in murine models [8] .
Vedolizumab is a humanized monoclonal antibody that selectively recognizes the α 4 β 7 integrin present on circulating lymphocytes and inhibits their relocation to the GI tract [9] . Through inhibition of alloreactive lymphocyte migration to the gut, vedolizumab has shown to be effective in the treatment of inflammatory bowel disease (IBD), both in Crohn's disease [10] and ulcerative colitis (UC) [11] . A case series of patients with LGI a-GVHD treated with vedolizumab described a significant and durable response in the majority of participants [12] , though these findings were not replicated in a different study [13] . To further facilitate our understanding of the role of vedolizumab in LGI a-GVHD, we report on the results of patients treated with vedolizumab for LGI a-GVHD at our institution.
Methods
We conducted a retrospective case series of patients at our institution (a large, tertiary care hospital located in a major US city) with LGI a-GVHD who were treated with vedolizumab. Vedolizumab is non-formulary (NF) for inpatient use at our hospital, and its use is tracked by our pharmacy because of its NF status. Vedolizumab was provided by the hospital pharmacy as a standard drug (not through a grant) after it was approved for inpatient post-ASCT patients with severe, refractory LGI a-GVHD. Patients were identified through pharmacy records, and relevant patient data were obtained through chart review. Nine patients were identified, and all met inclusion criteria. Inclusion criteria included: age ≥18 years, biopsy-proven LGI a-GVHD prior to the initiation of vedolizumab, and completion of at least one dose of vedolizumab. The study was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai. Of note, there is an ongoing, separate, phase II trial at our institution LGI and liver
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LGI, liver and skin LGI GVHD clinical stage   II   II   III   III   III   IV   IV   IV   I LGI GVHD histologic stage incorporating vedolizumab with steroids for LGI a-GVHD; patients in that trial are not included in this analysis. The majority of patients in this study started vedolizumab prior to initiation of this clinical trial. Histologic grading was determined using the system developed by Floisand et al. [12] , itself a modification of the system proposed by Lerner et al. [14] . Histologic grading was as follows: Grade 1-isolated apoptotic cells without crypt loss, Grade 2-loss of isolated crypts without loss of contiguous crypts, Grade 3-loss of two or more contiguous crypts, Grade 4-extensive crypt loss with mucosal denudation. Clinical staging was based on both stool volume and abdominal pain, in accordance with criteria proposed by Glucksberg et al. [15] . Clinical staging was determined based on stool volume as follows: Stage 0 -≤500 cc/day, Stage 1 ->500 cc/day, Stage 2 ->1000 cc/ day, Stage 3 ->1500 cc/day, Stage 4 ->2000 cc/day or severe abdominal pain with or without ileus.
Concurrent
Vedolizumab was administered to all patients in accordance with the dose and schedule utilized in the treatment of IBD [10, 11] . Patients received an initial dose of 300 mg vedolizumab IV at week 0, followed by an additional 300 mg IV at week 2 and week 6, based upon response, functional status, and disease status at the time of scheduled dosing. After week 6, infusions are given every 8 weeks according to disease status and serum vedolizumab concentration. No patient in this series received an infusion after week 6.
Results
Nine patients, six males and three females, were included. Patients were a median of 44 years of age (range, 28-69 years) and were a median of 164 days (range, 36-327 days) post-ASCT at the start of vedolizumab. At baseline, patients had failed treatment with a median of 3 (range, 2-6) immunosuppressive (IS) regimens, including steroids in all patients. One patient had histologic grade I LGI a-GVHD before vedolizumab, two had histologic grade II involvement, and three each had histologic grade III and IV involvement. Clinically, one patient had stage II disease, two patients had stage III disease, and the remaining six patients had stage IV disease. Four patients had a documented active infection at the start of vedolizumab, of which three were intra-abdominal. Patients were followed for a median of 22 days (range, 6-107 days) after their first dose of vedolizumab. Additional baseline data can be found in Table 1 .
Two patients died within 1 week of vedolizumab initiation, and an additional four died before 1 month. At 10 days after starting vedolizumab, decreased stool volume was noted in four of seven patients, and abdominal pain was improved in one out of five patients. The three patients who survived past 4 weeks postvedolizumab initiation all experienced a decrease in stool output and improvement in abdominal pain at their 4-week follow-up.
At their last known follow-up, eight patients were on steroids and eight patients remained on two or more IS regimens. Eight deaths occurred within 60 days (range, 7-59 days) of starting vedolizumab. Seven of eight deaths were due to infection. Although four patients were receiving treatment for active infections at the time of vedolizumab initiation, only one of the patients died as a result of the documented initial infection. Of the other six deaths due to infection, five were suspected to have originated from the GI tract. The remaining death was due to renal failure and a decision to forgo dialysis. One patient was alive at their last known follow-up at 107 days. Additional outcome data can be found in Table 2 . Three patients had repeat biopsies for refractory symptoms following initiation of vedolizumab. All patients had completed one dose of vedolizumab at the time of the repeat biopsy. Although no change in histologic grading was noted for any patient using the pre-specified criteria, two biopsies were noted to be consistent with response to treatment, based on evaluation by clinical pathologists.
Discussion
Vedolizumab is effective in the treatment of IBD but its role in LGI a-GVHD is unclear. Patients in this case series had a high mortality rate following initiation of vedolizumab. Six of nine patients passed prior to 4-week follow-up, and only one patient survived past 2 months. Histologically, no improvement was seen in patients with a repeat biopsy after vedolizumab, though regenerative changes were noted on pathology reports. Although these results are largely negative, patients alive after 4 weeks of starting did have decreased abdominal pain and stool output. Notably, almost all patients died of infection or sepsis following vedolizumab, with five of these suspected to be of GI origin. It is important to note that these were all inpatients with complicated hospital courses with multiple prior infections and often had concurrent initiation of other immunosuppressive medications in the setting of acute GVHD. The risk of infection was not significantly increased in either major IBD trial with vedolizumab [10, 11] , though these were healthier populations, and the trials excluded relatively immunocompromised patients. Nevertheless, the possible risk of infection in this heavily immunocompromised population should be strongly considered prior to initiation of off-label therapy.
An initial case series [12] reported positive outcomes of vedolizumab for LGI a-GVHD, though a later study [13] reported an observed high mortality rate and low therapeutic utility. The patient baseline characteristics in our case series are decidedly more similar to the patients in the latter study. Whereas the original cohort of patients in Floisand et al. started vedolizumab as second-line therapy and had isolated LGI a-GVHD, the majority of patients in our study had multiple sites of GVHD involvement and started vedolizumab as third-or fourth-line therapy. Although the majority of patients passed away prior to their 4-week follow-up, those surviving past that point did exhibit some clinical response. It remains possible that vedolizumab may be effective for LGI a-GVHD in patients with good baseline functional status and lower risk of infection. Further research, including an ongoing phase II study at our institution focused on vedolizumab incorporation for steroid-refractory disease, will help elucidate the role of vedolizumab for LGI a-GVHD.
